Neoclease is a biotechnology company pioneering AI-designed gene-editing therapies optimized for individual genes. Using a proprietary platform that integrates generative protein models with synthetic biology, Neoclease builds ultra-precise, delivery-ready nucleases for diseases with high unmet need. Its lead program targets LRRK2 to halt progression of Parkinson’s disease. Neoclease’s approach enables the development of editors with enhanced specificity, efficiency, and size, unlocking new possibilities across thousands of genetic diseases.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Boston , Massachusetts , Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.neoclease.ai/
- Keywords
- gene editing, synthetic biology, AI/ML for drug discovery, neurodegeneration, protein engineering, gene therapy.
- HQ
- Boston , Massachusetts
Neoclease Questions
Neoclease's website is https://www.neoclease.ai/
Neoclease's LinkedIn profile is https://www.linkedin.com/company/neoclease
Neoclease has
4 employees.
View email and phone details for 4
employees at Neoclease.
Neoclease's industry is
Biotechnology Research
Neoclease's top competitors are
Externa Biosciences,
Matrisome Bio,
Coagulo Medical Technologies, Inc.,
C10 Labs,
Interon Laboratories, Inc.,
Nucleate Boston,
Phagepro,
Lybra Bio,
Dacapo Brainscience,
Kiragen Bio.
Neoclease's categories are Biotechnology Research
Neoclease's founding year is 2022
